Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

David M. Hyman,Ben Tran,Luis Paz-Ares,Jean-Pascal Machiels,Jan H. M. Schellens,Philippe L. Bedard,Mario Campone,Philippe Cassier,John Sarantopoulos,Ulka N. Vaishampayan,Rashmi Chugh,Amit Mahipal,A. Craig Lockhart,Cristiana Sessa,Thomas Zander,Matthew C.H. Ng,Giuseppe Curigliano,Jennifer Bendiske,Xueying Chen,Somesh Choudhury,Diana Graus-Porta,Nancy Lewis,Jose P. Garcia,Maria Jose de Miguel Luken

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

2019

PURPOSEConcurrent PIK3CA mutations and fibroblast growth factor receptor (FGFR) alterations occur in multiple cancer types, including estrogen receptor–positive breast cancer, bladder cancer, and e...

Keywords:

Mutant
Multiple cancer
Estrogen
Bladder cancer
Cancer research
Breast cancer
FGFR Inhibition
Medicine
Fibroblast growth factor receptor
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations